Navigation Links
GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimer's Disease Candidate Vaccines
Date:10/23/2008

VIENNA, Austria, October 23 /PRNewswire/ -- GlaxoSmithKline Biologicals S.A. (GSK) and AFFiRiS GmbH announced today the execution of a collaboration agreement granting GSK exclusive rights to AFFiRiS's Alzheimer's disease vaccine programmes, aimed at treating Alzheimer's by targeting beta-amyloid.

As part of the agreement GSK is acquiring exclusive rights to develop and commercialise two Alzheimer's disease vaccine candidates that are based on AFFiRiS AFFiTOPE technology and are currently in Phase I clinical development. AFFiRiS is also granting GSK an exclusive option to develop and commercialise alternative Alzheimer's disease vaccine candidates which are in preclinical development.

Under the terms of the agreement, AFFiRiS will receive an up-front payment of EUR 22.5 million (GBP17.5 million) and could be eligible for future milestone payments and royalties. The total potential value of the agreement could reach EUR 430 million (GBP334 million) in the event of full commercial success of the candidate vaccines. This agreement is subject to governmental authority approval.

Central to the deal is the AFFiRiS AFFiTOPE technology which allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing "rogue" human proteins such as beta-amyloid which is central to the pathology of Alzheimer's disease.

Commenting on the agreement, Walter Schmidt, co-founder and CEO of AFFiRiS, stated: "We are pleased that we could secure GSK Biologicals, one of the world's leading vaccine companies, in collaborating on the development our Alzheimer's disease vaccine programs. This deal brings together two companies with strong innovation, vaccine development and commercialisation capabilities and experience."

Jean Stephenne, President and General Manager of GlaxoSmithKline Biologicals, said "We are impressed with the AFFiRiS technology - combined with our expertise in innovative adjuvant systems this collaboration will improve our chance of success in the discovery of new treatments against this major disease."

Frank Mattner, co-founder and CSO of AFFiRiS, added: "For the treatment of chronic diseases, our AFFiTOPE technology has the potential to deliver innovative vaccines capable of inducing immune responses, with the possibility of beneficial therapeutic effects. We hope that this agreement will ultimately deliver a therapeutic benefit to Alzheimer's patients."

Notes to Editors

About GSK GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit http://www.gsk.com.

About GlaxoSmithKline Biologicals GlaxoSmithKline Biologicals (GSK Biologicals) is a global vaccine company which has shown to be a leader in innovation. The company is active in the fields of vaccine research, development and production with over 30 vaccines approved for marketing and 20 more in development. Headquartered in Belgium, GSK Biologicals has 14 manufacturing sites strategically positioned around the globe. In 2007 GSK Biologicals distributed 1.1 billion doses of vaccines to 169 countries in both developed and the developing world - an average of 3 million doses a day. GSK Biologicals employs over 9,000 people worldwide including more than 1,600 passionate scientists engaged in research aimed at discovering innovative vaccines that contribute to the health and well-being of people of all generations around the world.

About AFFiRiS AFFiRiS GmbH develops peptide-based vaccines for the treatment of Alzheimer's disease, atherosclerosis and other diseases that urgently require a medical solution. The company has established platform technologies and has a worldwide patent portfolio covering their vaccine candidates. The company employs 35 highly qualified members of staff on 600msquared of rented laboratory facilities at the Campus Vienna Biocenter (http://www.affiris.com).

GlaxoSmithKline Enquiries:

UK Media enquiries: Philip Thomson, +44(0)20-8047-5502; Claire Brough,

+44(0)20-8047-5502; Alice Hunt, +44(0)20-8047-5502; Gwenan White,

+44(0)20-8047-5502

US Media enquiries: Nancy Pekarek, +1-919-483-2839; Mary Anne Rhyne,

+1-919-483-2839; Sarah Alspach, +1-215-751-7709

European Analyst/Investor enquiries: David Mawdsley, +44(0)20-8047-5564;

Sally Ferguson, +44(0)20-8047-5543; Gary Davies, +44(0)20-8047-5503

US Analyst/ Investor enquiries: Tom Curry, +1-215-751-5419

AFFiRiS GmbH Enquiries: Campus Vienna Biocenter 2, 1030 Vienna, Austria

Dr. Walter Schmidt +43-1-798-1575-10

Distribution: PR&D - Public Relations for Research & Education Campus

Vienna Biocenter 2 1030 Vienna Austria, T +43-1-505-70-44,

E contact@prd.at, W: http://www.prd.at


'/>"/>
SOURCE AFFiRiS GmbH, GlaxoSmithKline Biologicals (GSKBiologicals)
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GlaxoSmithKline and Cellzome Announce Major Strategic Alliance
2. GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza(R)
3. GlaxoSmithKline To Post Quarterly US Grants Report
4. GlaxoSmithKline - Q2 Results and Strategy Update - Interview with CEO
5. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
6. CDC Immunization Advisory Committee Recommends Two New Pediatric Vaccines from GlaxoSmithKline
7. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
8. GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
9. GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience
10. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
11. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 22, 2016  Amgen (NASDAQ: AMGN ... QB3@953 life sciences incubator to accelerate the ... shared laboratory space at QB3@953 was created to help ... obstacle for many early stage organizations - access to ... sponsorship, Amgen launched two "Amgen Golden Ticket" awards, providing ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
(Date:6/22/2016)... ... June 22, 2016 , ... Quantitative Radiology Solutions, ... and current participant in the Phase 1 Ventures program, is leveraging regional and ... Quantitative Radiology Solutions helps physicians make better treatment decisions by quantifying medical imaging ...
(Date:6/22/2016)... ... 22, 2016 , ... The Immigrant Journey Awards , ... to North Texas and the nation, recently held its annual luncheon program. ... civic and economic vitality of North Texas. Proceeds from the event are used ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):